A 53-year-old man with end-stage kidney disease on haemodialysis thrice weekly for 32 years due to purpura nephritis presented with exertional dyspnoea and fever. Chest radiograph revealed nodular shadows in the periphery of lung areas, especially bilateral upper lung areas (Figure 1) , and computed tomography of the chest revealed high dense foci of a ground-glass appearance in bilateral upper lung areas (Figure 2A ). At first, he was suspected to have infectious pneumonitis, because of opportunistic condition due to long-lasting steroid use and immunosuppressive therapy for recurrent episodes of purpura. However, the symmetrical and upper lung distribution of the lesions raised the possibility of metastatic pulmonary calcification (MPC). A Technetium 99 methylene diphosphonate (Tc99m-MDP) bone scan was then performed and an increased uptake in the upper lobe lesions ( Figure 2B ) confirmed the diagnosis of MPC. Indeed, respiratory function tests noted a restrictive pattern.
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The review of the medical history revealed that he had undergone a total parathyroidectomy for secondary hyperparathyroidism 17 years ago and, subsequently, developed adynamic bone disease. For hypocalcaemia, he had been taking large doses of calcium carbonate and alfacalcidol for a long term. His recent intact parathyroid hormone level was 15 pg/ml, serum calcium 9.0 mg/dl, serum phosphate MPC in a patient with long dialysis vintage 501 2.2 mg/dl, and calcium phosphate product 19.8 mg 2 /dl 2 . Doses of calcium carbonate and vitamin D were reduced to a minimum to maintain normocalcaemia.
MPC was found to be common (60-80%) by bone scan or autopsy among dialysis patients and can cause restrictive lung disease, however, rarely manifests overt symptoms and is often overlooked. Pathogenesis of MPC still remains to be determined but is suspected to be associated with bone and mineral disorders as in other ectopic calcification. Therefore, reduction of calcium-containing medication, vitamin D or its analogues is a mainstay for the management of MPC.
